Compare Recursion Pharmaceuticals Inc (RXRX) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Taskus Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Taskus Inc trades at $5.86 (market cap $532.07M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.9× Taskus Inc's market cap. Which is the better fit depends on your goals.
| RXRX | TASK | |
|---|---|---|
Market Cap | $1.53B | $532.07M |
Sector | Health | Technology |
52-Week High | $6.79 | $18.21 |
52-Week Low | $2.84 | $4.57 |
Enterprise Value | $946.50M | $927.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
TaskUs (TASK) trades at $5.81, down 0.34% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 earnings of $0.35 per share, missing estimates, after beating in the prior two quarters. Revenue reached $1.18 billion in 2025 with net income of $102.28 million, showing strong profitability. Analysts maintain a consensus buy rating with a $9.50 price target, suggesting significant upside potential.
The stock appears undervalued with a P/E of 5.16 and P/S of 0.45, supported by robust ROE of 26.52%. Risks include recent earnings miss and competitive pressures in digital services. Positive cash flow and debt reduction trends provide fundamental strength, but investor sentiment is mixed amid technical overbought signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
